Carter Gould
Stock Analyst at Cantor Fitzgerald
(4.33)
# 1,338
Out of 5,088 analysts
646
Total ratings
55%
Success rate
7%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $53 | $58.83 | -9.91% | 38 | Oct 30, 2026 | |
| GILD Gilead Sciences | Maintained: Buy | $155 → $175 | $153.07 | +14.33% | 53 | Oct 30, 2026 | |
| MRK Merck & Co. | Maintained: Hold | $145 | $143.63 | +0.95% | 47 | Oct 27, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $595 | $501.95 | +18.54% | 12 | Oct 26, 2026 | |
| PCVX Vaxcyte | Reiterated: Buy | $120 | $63.68 | +88.44% | 3 | Oct 12, 2026 | |
| ABBV AbbVie | Rated: Buy | $285 → $290 | $282.68 | +2.59% | 51 | Oct 8, 2026 | |
| AMGN Amgen | Rated: Hold | $400 → $440 | $424.94 | +3.54% | 52 | Oct 8, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,410 → $1,440 | $1,240.34 | +16.10% | 102 | Oct 8, 2026 | |
| PFE Pfizer | Rated: Hold | $27 → $28 | $29.44 | -4.89% | 62 | Oct 8, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $750 → $795 | $782.04 | +1.66% | 53 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $62.65 | - | 18 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $233.48 | n/a | 45 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.43 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $50.49 | n/a | 24 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $18.05 | n/a | 14 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $1.20 | n/a | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $1.95 | n/a | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $136.98 | n/a | 29 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $160 | $191.42 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $95.29 | n/a | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | €82.81 | €144.35 | n/a | 1 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $82 → $86 | $113.25 | n/a | 4 | Jul 31, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $94 | $543.15 | n/a | 1 | May 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $4 | $2.44 | n/a | 2 | Feb 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $2.8 | $6.08 | n/a | 2 | Jan 11, 2019 |
Bristol-Myers Squibb Company
Oct 30, 2026
Maintained: Hold
Price Target: $53
Current: $58.83
Upside: -9.91%
Gilead Sciences
Oct 30, 2026
Maintained: Buy
Price Target: $155 → $175
Current: $153.07
Upside: +14.33%
Merck & Co.
Oct 27, 2026
Maintained: Hold
Price Target: $145
Current: $143.63
Upside: +0.95%
Vertex Pharmaceuticals
Oct 26, 2026
Reiterated: Buy
Price Target: $595
Current: $501.95
Upside: +18.54%
Vaxcyte
Oct 12, 2026
Reiterated: Buy
Price Target: $120
Current: $63.68
Upside: +88.44%
AbbVie
Oct 8, 2026
Rated: Buy
Price Target: $285 → $290
Current: $282.68
Upside: +2.59%
Amgen
Oct 8, 2026
Rated: Hold
Price Target: $400 → $440
Current: $424.94
Upside: +3.54%
Eli Lilly and Company
Oct 8, 2026
Rated: Buy
Price Target: $1,410 → $1,440
Current: $1,240.34
Upside: +16.10%
Pfizer
Oct 8, 2026
Rated: Hold
Price Target: $27 → $28
Current: $29.44
Upside: -4.89%
Regeneron Pharmaceuticals
Jul 30, 2026
Reiterated: Buy
Price Target: $750 → $795
Current: $782.04
Upside: +1.66%
Feb 25, 2026
Reiterated: Buy
Price Target: n/a
Current: $62.65
Upside: -
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $233.48
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $8.43
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $50.49
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $18.05
Upside: n/a
Nov 8, 2024
Rated: Buy
Price Target: $9
Current: $1.20
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $12
Current: $1.95
Upside: n/a
Oct 31, 2024
Reiterated: Buy
Price Target: $160
Current: $136.98
Upside: n/a
Jan 11, 2023
Rated: Hold
Price Target: $160
Current: $191.42
Upside: n/a
Dec 7, 2022
Initiated Coverage: Buy
Price Target: $37
Current: $95.29
Upside: n/a
Feb 27, 2020
Initiated Coverage: Buy
Price Target: €82.81
Current: €144.35
Upside: n/a
Jul 31, 2019
Reiterated: Hold
Price Target: $82 → $86
Current: $113.25
Upside: n/a
May 17, 2019
Upgraded: Hold
Price Target: $94
Current: $543.15
Upside: n/a
Feb 1, 2019
Downgraded: Hold
Price Target: $16 → $4
Current: $2.44
Upside: n/a
Jan 11, 2019
Reiterated: Hold
Price Target: $6 → $2.8
Current: $6.08
Upside: n/a